UCapital NewsBusiness Super App · news connected to data, companies, people and deals
IT
VoicesWire
LIVE
BREAKING LIVE

The news moving markets, right now

From international newswires in real time. For every story the News Impact AI agent estimates the market impact and flags the assets to watch, with the story’s impact on each: positive, negative or neutral.

STORIES TODAY
797
via finance.yahoo.comBusiness & Companies

Elevar Therapeutics: FDA sets April 9, 2027 PDUFA date for rivoceranib with camrelizumab

FROM THE WIRE · FINANCE.YAHOO.COM

Elevar Therapeutics FDA assigns a PDUFA target action date of April 9, 2027 Combination achieved a median overall survival of 23.8 months in patients with unresectable or metastatic HCC, compared to sorafenib's mOS of 15.2 months FORT LEE, N.J., Nov. 05, 2026 (GLOBE NEWSWIRE)…

Read at the source ↗
MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: neutralThe regulatory review of an oncology drug matters for HLB's subsidiary, but the decision is far off.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
  1. 01The FDA acknowledged the resubmitted NDA for rivoceranib with camrelizumab.
  2. 02The PDUFA target action date is April 9, 2027.
  3. 03The combination showed median overall survival of 23.8 months versus 15.2 months for sorafenib.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
HLB Co., Ltd.028300.KQStock32,400.00 KRWMarket closedtoday -3.28%Neutral
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets

ALL BREAKING TODAY

Breaking live stories come from third-party newswires via feed; headline and summary belong to the stated source. Impact analysis: UCapital AI · News Impact.

UCapital News is the news section of UCapital24 S.p.A. All content is for information purposes only and does not constitute financial advice, a recommendation or a solicitation to invest. Even where terms such as “buy”, “sell”, “bullish” or “bearish”, or asset impact signals, appear, they only indicate the possible effect of a news item on the markets and are not an invitation to buy or sell financial instruments. News is analysed with UCapital AI and may also be published via API feeds from third-party providers, to give our users a continuous flow of news. UCapital24 S.p.A. accepts no liability of any kind for decisions made on the basis of this content. Wire releases are published by companies and are not verified by the newsroom.

AI use policy. UCapital AI supports the newsroom with news analysis, summaries, market reactions, translations and the generation of cards and charts. AI-generated or AI-assisted content is labelled in the byline (AI Desk, a named AI profile marked «AI», or joint byline) and is reviewed by editors before publication. News received via API feeds from third-party providers is attributed to the original source. AI can make mistakes: report any inaccuracies to the newsroom. Users’ personal data is not used to train the models.